Martin Andrew Burian Buys 67,000 Shares of Nanalysis Scientific Corp. (CVE:NSCI) Stock

Nanalysis Scientific Corp. (CVE:NSCI) Director Martin Andrew Burian bought 67,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were purchased at an average cost of C$0.28 per share, for a total transaction of C$18,760.00.

Nanalysis Scientific Stock Performance

NSCI stock traded up C$0.02 during midday trading on Thursday, hitting C$0.29. The company’s stock had a trading volume of 115,500 shares, compared to its average volume of 55,559. The stock has a market cap of C$32.79 million, a price-to-earnings ratio of -2.29 and a beta of 0.72. Nanalysis Scientific Corp. has a 1 year low of C$0.26 and a 1 year high of C$0.60. The company has a quick ratio of 1.11, a current ratio of 1.42 and a debt-to-equity ratio of 71.72. The stock’s 50-day moving average price is C$0.36 and its 200 day moving average price is C$0.39.

Nanalysis Scientific Company Profile

Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies.